The TRAILBLAZER-ALZ 3 Clinical Research Study is evaluating the safety and effectiveness of an investigational drug for those at risk of developing symptoms of Alzheimer’s disease.

The study involves people who have normal memory, thinking, mood and behavior patterns.

Participants are randomly assigned to one of two groups. They receive either the investigational drug or a placebo (a substance that looks like the investigational drug but contains no active ingredients). Those who receive placebo may have the option to receive the investigational drug at a later time.  

If you qualify, participation can last as long as approximately 4.5 years, but will vary for each participant.

    Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.